Tous les communiqués de presse

- Valbiotis announces upcoming organizational changes of its Board of Directors.

Voir le communiqué de presse

- Valbiotis presents its 2022 financial communication calendar

Voir le communiqué de presse

- Valbiotis announces approval to launch the two Phase II/III INSIGHT and INSIGHT 2 clinical studies, the last step in the development of TOTUM•854 for the reduction of blood pressure.

Voir le communiqué de presse

- Icare Group, an expert in the control of health product safety, has created the customizable mask holder (IN FRENCH).

Voir le communiqué de presse

- Fourth quarter 2021 financial information (IN FRENCH)

Voir le communiqué de presse

- Carbios accelerates its industrial development.

Voir le communiqué de presse

- Increased momentum in the clinical newsflow for major indications: results expected in 2022 for prediabetes, hypercholesterolemia and high blood pressure.

Voir le communiqué de presse

- 10 December 2021 Ordinary General Meeting – Procedures for availability of preparatory documents (IN FRENCH).

Voir le communiqué de presse

- Update on the METEX NØØVISTA activity (IN FRENCH).

Voir le communiqué de presse

- Valbiotis announces positive preclinical results for TOTUM•070 in hypercholesterolemia, selected and presented at the American Heart Association (AHA) annual meeting.

Voir le communiqué de presse